Arlene Siefker-Radtke, MD, is Professor of Genitourinary Medical Oncology at the University of Texas, MD Anderson Cancer Center, Houston, TX, USA, and is Clinical Co-Leader of the MD Anderson Bladder Specialized Program of Research Excellence (SPORE).
Dr Siefker-Radtke completed her medical degree from Johns Hopkins University School of Medicine and her residency training in internal medicine at the New England Medical Center Hospital in Boston. She received her fellowship in medical oncology at MD Anderson.
Dr Siefker-Radtke’s research focus is on developing effective therapies for the treatment of urothelial cancer and other rare tumors of the bladder. She is well known for her novel clinical trial designs as well as the development of novel agents and targets including immunotherapy.